ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Infanrix hexa, Pulver und Suspension zur Herstellung einer Injektionssuspension - 10 x 1
00640004 GlaxoSmithKline AG
Infanrix hexa, Pulver und Suspension zur Herstellung einer Injektionssuspension02.10.2000
  02.10.2000
Diphtheria-Haemophilus Influenzae B-Pertussis-Poliomyelitis-Tetanus-Hepatitis B (J07CA09) 
WHO-DDD 
08.08.10 x 1
08.08. 
B  
No 
IP 
PR  
k.A.PR
  
7680006400047Impfstoffe
  
Composition
I) DTPa-HepB-IPV: toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U.I., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U.I., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U.I., hepatitidis B viri antigenum ADNr 10 µg, aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, aluminium 0.2 mg ut aluminii phosphas, natrii chloridum corresp. natrium 1.8 mg, medium 199, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini B sulfas, formaldehydum, polysorbatum 20, polysorbatum 80. II) Hib: polysaccharida haemophili influenzae typus B 20752 conjugata cum toxoido tetani 10 µg, lactosum, aluminium 0.12 mg ut aluminii phosphas, pro praeparatione. I) et II) corresp. DTPa-HepB-IPV + Hib: toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U.I., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U.I., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U.I., hepatitidis B viri antigenum ADNr 10 µg, polysaccharida haemophili influenzae typus B 20752 conjugata cum toxoido tetani 10 µg, aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, aluminium 0.32 mg ut aluminii phosphas, natrii chloridum corresp. natrium 1.8 mg, medium 199, lactosum, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini B sulfas, formaldehydum, polysorbatum 20, polysorbatum 80.
Packungsbestandteile
II
 
Injection suspension 
  
  
BAG: Active AgentDose
 25 mcg
 10 mcg
 8 mcg
 30 UI
 25 mcg
 40 UI
 10 mcg
 40 UI
 8 UI
 32 UI
 
Inactive agentsDose
  
 10 µg
  
 20752
 
I
 
Injection suspension 
  
 
Active AgentDose
 25µg / 0.5ml
 10µg / 0.5ml
 8µg / 0.5ml
 30U.I. / 0.5ml
 25µg / 0.5ml
 40U.I. / 0.5ml
 40U.I. / 0.5ml
 8U.I. / 0.5ml
 32U.I. / 0.5ml
BAG: Active AgentDose
 25 mcg
 10 mcg
 8 mcg
 30 UI
 25 mcg
 40 UI
 10 mcg
 40 UI
 8 UI
 32 UI
 
Inactive agentsDose
  
  
 199
Sodium Chloride 
 
Source
Data was imported : 08.11.2023 Swissmedic Registration : Sequence : Product name : Registration owner: : Product group : Index Therapeuticus (BSV) : Medication Code : Date of registration : Valid until : Package number : Show package size : Commercial Form/Unit : Swissmedic categorie. : Active Agents : Composition :
 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home